Aims-To monitor the expression of intercellular adhesion molecule I (ICAM-I) in vitro after stimulation of human macrophages with Plasmodium falciparum antigens, as well as the plasma concentrations of soluble ICAM-I (SICAM-I) in vivo in malarial patients. Methods-Human mononuclear leucocytes were cultured and stimulated for four hours with 300 nglml exogenous P falciparum antigens. CD14 and CD54 (ICAM-I) expression was monitored using flow cytometry. Soluble ICAM-I (s ICAM-I) was also measured in the blood of 122 outpatients with malaria before and after treatment (Rio Branco, Acre, Brazil). Results-ICAM-I expression increased from 15% to 375% after four hours of stimulation. When sICAM-I was analysed in the plasma of 122 patients with Pfalciparum or Plasmodium vivax malaria by enzyme immunoassay, significant increases were found. These were more pronounced in patients with P falciparum malaria, compared with healthy controls, and with the same patients four weeks after treatment. Conclusion-ICAM-I expression may also be upregulated in human macrophages by exogenous Plasmodium antigens as well as by cytokines during the acute phase of malaria. sICAM-I concentrations are downregulated after treatment, probably caused by the absence of circulating Plasmodium antigens.
pronounced in patients with P falciparum malaria, compared with healthy controls, and with the same patients four weeks after treatment. Conclusion-ICAM-I expression may also be upregulated in human macrophages by exogenous Plasmodium antigens as well as by cytokines during the acute phase of malaria. sICAM-I concentrations are downregulated after treatment, probably caused by the absence of circulating Plasmodium antigens. ( In this study the induction of ICAM-I expression in human macrophages was investigated after stimulation with malarial antigens, as well as the variations in the concentrations of sICAM-I in the blood of different groups of malarial patients before and after treatment.
Methods
For in vitro experiments, human mononuclear leucocytes were isolated from buffy coats from healthy adults, using Ficollhypaque density gradients, as described before. 17 The separated cells were cultured and stimulated for four hours with malarial antigens. 17 CD14 and CD54 (ICAM-I) expression was monitored by flow cytometry (FACSCAN, Becton Dickinson, Heidelberg, Germany).
One hundred and twenty two outpatients attending a health care centre in Rio Branco, Acre, Brazil had either untreated, uncomplicated P falciparum malaria (n = 44; nine women, 35 men; median age 22 years, range 16-50 years) or P vivax malaria (n = 78; 18 females, 60 males; median age 22 years, range 3-81 years). In an arbitrary classification, '8 patients with P falciparum malaria were considered "non-immune" if they had had two or fewer malaria attacks during their life (n = 28). Those who had had malaria three or more times in the preceding two years were classified as "semi-immune" (n = 16).
Fifteen healthy subjects from Rio Branco of similar gender and age distribution served as controls. None of them developed parasitaemia during the follow up period of 28 days.
All the patients infected with P falciparum received oral clindamycin 5 mg/kg twice daily for five consecutive days, as described elsewhere. '9 20 Those infected with P vivax received a total of 25 mg/kg oral chloroquine for two days and 0-25 mg/kg primaquine daily for 14 consecutive days. Plasma samples were collected from all patients on admission (day 0) and 28 days after treatment had started and stored at -20°C until analysis.
Parasitaemia was determined by drawing 10 Ml blood (fingerprick), distributed equally on an 18 x 10 mm area of a glass slide. After Giemsa staining, the parasite species was identified and the number of parasites counted per 100 oil-immersion fields ( x 1000). The count was multiplied by four to yield the number of parasites per 1 jul of blood.21
Plasma concentrations of ac-proteinase inhibitor (API), a, acid glycoprotein (AAG), and C-reactive protein (CRP) were measured by radioimmunodiffusion using commercially available test kits (Partigen, Behring Austria). Plasma concentrations of sICAM-I were assayed using a commercially available enzyme immunoassay (Bender, Austria). All samples were tested in duplicate and sICAM-I concentrations were determined by comparing the mean absorption of duplicate samples with that of a standard curve. The sensitivity of the test was about 0 5 ng/ml.
Statistical analysis was performed using the Mann-Whitney U test and the Spearman rank correlation coefficient. The level of significance was set at 0-05.
Results
The effect of Pfalciparum exogenous antigens ciparum exogenous antigens at a standard concentration of 300 ng/ml. Malarial antigens induced variable increases in ICAM-I expression (15% to 375%). Most of the cells showing upregulated ICAM-I expression were monocytes or macrophages, determined using simultaneously phycoerythrin (PE) labelled anti-CD14 antibodies.
In the study of malarial patients in Acre, Brazil, all patients had been radically cured by day 28 of follow up. The concentrations of sICAM-I in plasma from the different groups of analysed patients before and after treatment are shown in fig 2. Median values from "non-immune" (G2) and "semi-immune" (G3) patients infected with Pfalciparum were compared with the corresponding median values from those infected with P vivax (G4) and with healthy controls (Gl). Significantly lower values were detected in the control group than in both the malarial groups. Both the "non-immunes" and the "semi-immunes" of the patients infected with Pfalciparum had significantly higher concentrations of sICAM-I than patients infected with P vivax before and after treatment. There was no correlation between parasitaemia and sICAM-I concentrations in any of the groups of patients studied. sICAM concentrations were still increased 28 days after treatment in all the patients and were most pronounced in infections with Pfalciparum.
The concentrations of acute phase reactants in plasma were analysed in all patients before and after treatment (table). Blood API concentrations were significantly lower in the control group than in "non-immune" P falciparum and P vivax malarial patients. There was no significant difference between the subgroups of patients infected with Pfalciparum. A correlation between parasitaemia and API concentrations was detected only in those with P falciparum malaria. Plasma AAG concentrations were significantly increased in all malarial patients. "Non-immune" patients API, AAG, and CRP in mg/100 ml plasma. *Difference from controls was significant (p < 0 05).
Groups of patients
tDifference from non-immunes" was significant. tDifference from P vivax group was significant.
ffDifference from day 28 value was significant.
"Correlation with parasitaemia was significant.
with Pfalciparum had higher initial concentrations than "semi-immune" patients, or than patients infected with P vivax. There was a positive correlation between parasitaemia and AAG plasma concentrations in patients with P falciparum. CRP concentrations discriminated best between the control group and all subgroups of malarial patients. There were also significant differences between "semiimmune" and "non-immune" patients infected with P falciparum, and between the "semi-immune" subgroup and the P vivax malarial patients. Correlations between the CRP concentrations and parasitaemia were found in both subgroups of P fakiparum patients, as well as in the P vivax patients.
Discussion
As far as we are aware, this is the first report about the induction of ICAM-I by malarial antigens. This effect is to be expected, however, as exogenous malarial antigens have been found to induce both TNF and IL-1 secretion,56 which would consequently induce the expression of ICAM-I. Remarkably, the maximal increases in ICAM-I expression found after four hours of stimulation with malarial antigens correspond with maximal TNF production as a response to in vitro stimulation of human mononuclear leucocytes with P falciparum exogenous antigens under similar conditions.17 Therefore, it is not possible to conclude whether ICAM-I upregulation is caused by the antigens directly or indirectly via an autocrine stimulatory pathway involving TNF and IL-1. The discovery of ICAM-I as one of the adhesion molecules responsible for sequestration in P falciparum malaria,22 as well as our own in vitro results, led to a further investigation of sICAM-I plasma concentrations in malarial patients. Indeed, high sICAM-I concentrations were found in patients with Pfalciparum malaria, and these decreased gradually after treatment with clindamycin. Although to a lesser degree, sICAM-I concentrations were also increased in patients with P vivax malaria. In the latter, no parasite sequestration occurs, raising the question of how sICAM-I concentrations and cellular expression of ICAM-I are associated with each other. As to the numerous conditions in which increased sICAM-I concentrations have been described, it is obvious that sICAM-I plasma concentrations are related to the amounts of cytokines released. The plasma concentrations of the acute phase proteins API, AAG, and CRP, induced by monokines, behave in a similar manner to sICAM-I, with the highest concentrations seen in "non-immune" patients with P falciparum malaria and the lowest concentrations in the "semi-immune" P falciparum and P vivax groups. However, unlike sICAM-I, differences between the increased concentrations of acute phase proteins were not significant in patients with Pfalciparum or P vivax malaria. This indicates that there might be specific differences associated with the role of sICAM-I in both groups of malarial patients.
The high concentrations of API, AAG, and CRP returned to lower levels comparable with those of healthy controls within four weeks of starting treatment, and this was especially noticeable for CRP, where a correlation with parasitaemia was also observed. This agrees with other studies, which have also shown a link between parasitaemia and CRP concentrations in patients infected with P falcipanum.2"5 Plasma sICAM-I concentrations behaved in a similar manner to those of acute phase proteins, but no correlation was found between sICAM-I concentrations and parasitaemia or the concentrations of any of the acute phase proteins analysed. This might have been due to the different kinetics of production and metabolism. Moreover, the upregulation of sICAM-I expression during the acute phase of malaria can be attributed to an increased release of cytokines,26 but whether sICAM-I has any any pathogenic role in malaria or merely represents an unspecific response to enhanced cytokine secretion and the presence of malaria antigens remains to be determined.
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